Form 4: Neurocrine Biosciences Director William H. Rastetter Reports Stock Transactions

Director William H. Rastetter reported the acquisition and disposal of Neurocrine Biosciences stock and restricted stock units.

Summary

• On May 22, 2025, Director William H. Rastetter reported transactions involving Neurocrine Biosciences Inc. stock.
• Rastetter acquired 2,869 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• He also acquired 3,318 restricted stock units on May 21, 2025, which will vest in full on May 21, 2026.
• Following these transactions, Rastetter directly owns 3,318 derivative securities and 40,360 shares of common stock, with 40,360 shares held indirectly through the Rastetter Family Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The acquisition of shares through RSU vesting could be seen as a slightly positive sign, but it's a routine transaction.

Positives

• The acquisition of shares through RSU vesting could be seen as a positive sign, indicating the director's continued alignment with the company's success.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The reported transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the director's actions.

Key Dates

Keywords

Neurocrine Biosciences, Director, Stock Transactions, RSU, Form 4, Beneficial Ownership, Rastetter